Anti-pilra antibodies, uses thereof, and related methods and reagents

Provided herein are anti-PILRA antibodies with the highly desirable selectivity: having comparable binding to cynomolgus and human PILRA proteins, but much weaker binding to human PILRB protein, as well as binding to both PILRA G78 and R78 variants. The binding and selectivity profiles of the antibo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DENALI THERAPEUTICS INC, WEERAKKODY Tanya N, KIM Do Jin, MONROE Kathryn M, SABELSTR?M Hanna, TH?OLIS JR. Richard, LISAINGO Kathleen, PARK Joshua I
Format:	Patent
Sprache:	eng ; heb
Schlagworte:	CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	DENALI THERAPEUTICS INC WEERAKKODY Tanya N KIM Do Jin MONROE Kathryn M SABELSTR?M Hanna TH?OLIS JR. Richard LISAINGO Kathleen PARK Joshua I
description	Provided herein are anti-PILRA antibodies with the highly desirable selectivity: having comparable binding to cynomolgus and human PILRA proteins, but much weaker binding to human PILRB protein, as well as binding to both PILRA G78 and R78 variants. The binding and selectivity profiles of the antibodies described herein allow for them to be used in animal studies (e.g., monkeys) without the need to rely on a surrogate molecule and also when treating subjects with either PILRA variant. Further described herein, for the first time, are biological discoveries related to PILRA and the effects of reducing PILRA signaling in cells.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IL313614A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IL313614A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IL313614A3</originalsourceid><addsrcrecordid>eNrjZHB1zCvJ1C3IzClKVEgEMpPyUzJTi3UUSotTixVKMlKLUvPTdIAyKQpFqTmJJakpCrmpJRn5KcVQscT01LySYh4G1rTEnOJUXijNzSDn5hri7KGbWpAfn1pckJicmpdaEu_pY2xobGZo4mhMUAEAkQYxfg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Anti-pilra antibodies, uses thereof, and related methods and reagents</title><source>esp@cenet</source><creator>DENALI THERAPEUTICS INC ; WEERAKKODY Tanya N ; KIM Do Jin ; MONROE Kathryn M ; SABELSTR?M Hanna ; TH?OLIS JR. Richard ; LISAINGO Kathleen ; PARK Joshua I</creator><creatorcontrib>DENALI THERAPEUTICS INC ; WEERAKKODY Tanya N ; KIM Do Jin ; MONROE Kathryn M ; SABELSTR?M Hanna ; TH?OLIS JR. Richard ; LISAINGO Kathleen ; PARK Joshua I</creatorcontrib><description>Provided herein are anti-PILRA antibodies with the highly desirable selectivity: having comparable binding to cynomolgus and human PILRA proteins, but much weaker binding to human PILRB protein, as well as binding to both PILRA G78 and R78 variants. The binding and selectivity profiles of the antibodies described herein allow for them to be used in animal studies (e.g., monkeys) without the need to rely on a surrogate molecule and also when treating subjects with either PILRA variant. Further described herein, for the first time, are biological discoveries related to PILRA and the effects of reducing PILRA signaling in cells.</description><language>eng ; heb</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240801&DB=EPODOC&CC=IL&NR=313614A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240801&DB=EPODOC&CC=IL&NR=313614A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DENALI THERAPEUTICS INC</creatorcontrib><creatorcontrib>WEERAKKODY Tanya N</creatorcontrib><creatorcontrib>KIM Do Jin</creatorcontrib><creatorcontrib>MONROE Kathryn M</creatorcontrib><creatorcontrib>SABELSTR?M Hanna</creatorcontrib><creatorcontrib>TH?OLIS JR. Richard</creatorcontrib><creatorcontrib>LISAINGO Kathleen</creatorcontrib><creatorcontrib>PARK Joshua I</creatorcontrib><title>Anti-pilra antibodies, uses thereof, and related methods and reagents</title><description>Provided herein are anti-PILRA antibodies with the highly desirable selectivity: having comparable binding to cynomolgus and human PILRA proteins, but much weaker binding to human PILRB protein, as well as binding to both PILRA G78 and R78 variants. The binding and selectivity profiles of the antibodies described herein allow for them to be used in animal studies (e.g., monkeys) without the need to rely on a surrogate molecule and also when treating subjects with either PILRA variant. Further described herein, for the first time, are biological discoveries related to PILRA and the effects of reducing PILRA signaling in cells.</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHB1zCvJ1C3IzClKVEgEMpPyUzJTi3UUSotTixVKMlKLUvPTdIAyKQpFqTmJJakpCrmpJRn5KcVQscT01LySYh4G1rTEnOJUXijNzSDn5hri7KGbWpAfn1pckJicmpdaEu_pY2xobGZo4mhMUAEAkQYxfg</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>DENALI THERAPEUTICS INC</creator><creator>WEERAKKODY Tanya N</creator><creator>KIM Do Jin</creator><creator>MONROE Kathryn M</creator><creator>SABELSTR?M Hanna</creator><creator>TH?OLIS JR. Richard</creator><creator>LISAINGO Kathleen</creator><creator>PARK Joshua I</creator><scope>EVB</scope></search><sort><creationdate>20240801</creationdate><title>Anti-pilra antibodies, uses thereof, and related methods and reagents</title><author>DENALI THERAPEUTICS INC ; WEERAKKODY Tanya N ; KIM Do Jin ; MONROE Kathryn M ; SABELSTR?M Hanna ; TH?OLIS JR. Richard ; LISAINGO Kathleen ; PARK Joshua I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IL313614A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; heb</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>DENALI THERAPEUTICS INC</creatorcontrib><creatorcontrib>WEERAKKODY Tanya N</creatorcontrib><creatorcontrib>KIM Do Jin</creatorcontrib><creatorcontrib>MONROE Kathryn M</creatorcontrib><creatorcontrib>SABELSTR?M Hanna</creatorcontrib><creatorcontrib>TH?OLIS JR. Richard</creatorcontrib><creatorcontrib>LISAINGO Kathleen</creatorcontrib><creatorcontrib>PARK Joshua I</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DENALI THERAPEUTICS INC</au><au>WEERAKKODY Tanya N</au><au>KIM Do Jin</au><au>MONROE Kathryn M</au><au>SABELSTR?M Hanna</au><au>TH?OLIS JR. Richard</au><au>LISAINGO Kathleen</au><au>PARK Joshua I</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Anti-pilra antibodies, uses thereof, and related methods and reagents</title><date>2024-08-01</date><risdate>2024</risdate><abstract>Provided herein are anti-PILRA antibodies with the highly desirable selectivity: having comparable binding to cynomolgus and human PILRA proteins, but much weaker binding to human PILRB protein, as well as binding to both PILRA G78 and R78 variants. The binding and selectivity profiles of the antibodies described herein allow for them to be used in animal studies (e.g., monkeys) without the need to rely on a surrogate molecule and also when treating subjects with either PILRA variant. Further described herein, for the first time, are biological discoveries related to PILRA and the effects of reducing PILRA signaling in cells.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; heb
recordid	cdi_epo_espacenet_IL313614A
source	esp@cenet
subjects	CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES
title	Anti-pilra antibodies, uses thereof, and related methods and reagents
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T02%3A56%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DENALI%20THERAPEUTICS%20INC&rft.date=2024-08-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIL313614A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true